A few years ago I served as president of the Tampa Bay chapter of JDRF. At the same time one of my good Pharmacist-CDE friends was president of the local ADA chapter, and we would always tease each other as to who was raising the most money for our respective …

Study finds diabetes complications and mortality may be better predicted with elevated 1-hour blood glucose levels compared with 2-hour blood glucose levels.

Congress creates abbreviated licensure pathway for biological products similar to or interchangeable with FDA-approved products.

Severe hypoglycemia in type 2 diabetes was found to be associated with increased cardiac failure and mortality.

Diastolic function begins to decline in early stages of type 2 diabetes.

Insulin found to provide better control of post-prandial glucose without significantly elevating hypoglycemia risk.

Do you believe that glucose monitors will be a thing of the past as continuous glucose monitors (CGM) become less expensive and more accurate? Follow the link to see how you and your colleagues compare!

A 54-year-old male presents to your office for an initial visit. His past medical history is significant for hypertension, hypertriglyceridemia and acute pancreatitis. His current lab results show an A1C 9.1%, which is confirmed on a repeat lab. You would like to start him on an antihyperglycemic treatment regimen. Which of the following two-drug combinations is contraindicated for this patient? A. Metformin + a sulfonylurea B. Metformin + an insulin C. Metformin + a meglitinide D. Metformin + a GLP-1 receptor agonist Follow the link to get the answer.

Once given FDA approval, the Senseonics Eversence System will be the fourth CGMS available in the U.S. It was submitted to the FDA for premarket approval last October, supported by data from a 90-patient pivotal trial of the device. The trial followed adults with type 1 or type 2 diabetes over 90 days of CGM sensor wearing. This is an implantable CGM system that is currently approved in Europe. The sensor sits just under your skin and can stay there for anywhere from 90-180 days.

Julia Greenstein, Ph. D. is the JDRF Vice President of Discovery Research, which includes early-stage programs across the JDRF portfolio. Dr. Greenstein has more than 20 years of experience in the corporate biotechnology arena, holding leadership positions that have helped accelerate discoveries to market.